Aurinia Pharmaceuticals reports Q3 EPS 10c, consensus 1c
The Fly

Aurinia Pharmaceuticals reports Q3 EPS 10c, consensus 1c

Reports Q3 revenue $67.8M, consensus $57.69M. “We are pleased to report continued strong momentum through the first nine months of the year,” stated CEO Peter Greenleaf. “Going forward, our streamlined organization will enable us to lean further into key areas of the commercial LUPKYNIS business that have historically delivered optimal returns, while at the same time accelerating the development of our important pipeline product, AUR200.”

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App